CA Patent

CA3168727A1 — Daptomycin formulation with branched aiphatic amino acid

Assigned to Xellia Pharmaceuticals ApS · Expires 2021-09-02 · 5y expired

What this patent protects

The present disclosure relates to a solid formulation of daptomycin comprising at least one branched aliphatic amino acid. Solid daptomycin formulation of the present disclosure shows improved reconstituted time. The disclosure further relates to a method of preparation of the so…

USPTO Abstract

The present disclosure relates to a solid formulation of daptomycin comprising at least one branched aliphatic amino acid. Solid daptomycin formulation of the present disclosure shows improved reconstituted time. The disclosure further relates to a method of preparation of the solid daptomycin formulation according to this disclosure.

Drugs covered by this patent

Patent Metadata

Patent number
CA3168727A1
Jurisdiction
CA
Classification
—
Expires
2021-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Xellia Pharmaceuticals ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.